{{Drugbox
| IUPAC_name = naphthalen-1-yl 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylate
| image = FDU-PB-22_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category =  
| legal_AU = 
| legal_CA = Schedule II
| legal_UK = 
| legal_US = 
| legal_DE = Anlage II
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1883284-94-3
| ATC_prefix =  
| ATC_suffix =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 85E88884ZQ
| PubChem = 119025888
| ChemSpiderID      = 29763739
| smiles            = O=C(OC1=C(C=CC=C2)C2=CC=C1)C3=CN(CC4=CC=C(F)C=C4)C5=C3C=CC=C5
| StdInChI          = 1S/C26H18FNO2/c27-20-14-12-18(13-15-20)16-28-17-23(22-9-3-4-10-24(22)28)26(29)30-25-11-5-7-19-6-1-2-8-21(19)25/h1-15,17H,16H2
| StdInChIKey       = RCEKSVIFQKKFLS-UHFFFAOYSA-N

<!--Chemical data-->
| C=26 | H=18 | F=1 | N=1 | O=2
| molecular_weight = 395.42 g/mol
}}

'''FDU-PB-22''' is an derivative of [[JWH-018]] that is presumed to be a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] and has been sold online as a [[designer drug]].<ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1279 | title=FDU-PB-22 | publisher=Southern Association of Forensic Scientists | accessdate=23 July 2015}}</ref><ref name="Uchiyama_2015">{{cite journal|first1=Nahoko|last1=Uchiyama|first2=Yoshihiko|last2=Shimokawa|first3=Ruri|last3=Kikura-Hanajiri|first4=Yosuke|last4=Demizu|title=A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N–OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products|journal=Forensic Toxicology|date=1 July 2015|issn=1860-8965|pages=244–259|volume=33|issue=2|doi=10.1007/s11419-015-0268-7|pmid=26257833|pmc=4525202|first5=Yukihiro|last5=Goda|first6=Takashi|last6=Hakamatsuka}}</ref>

==Pharmacology==
FDU-PB-22 acts as a [[full agonist]] with a [[Affinity (pharmacology)#Protein-ligand binding|binding affinity]] of 1.19nM at [[Cannabinoid receptor type 1|CB<sub>1</sub>]] and 2.43nM at [[Cannabinoid receptor type 2|CB<sub>2</sub>]] [[cannabinoid]] receptors.<ref>{{cite journal|first1=Cornelius|last1=Hess|first2=ClaraT.|last2=Schoeder|first3=Thanigaimalai|last3=Pillaiyar|first4=Burkhard|last4=Madea|title=Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice|journal=Forensic Toxicology|date=1 July 2016|issn=1860-8965|pages=329–343|volume=34|issue=2|doi=10.1007/s11419-016-0320-2|first5=ChristaE.|last5=Müller|pmid=27429655|pmc=4929166}}</ref>

== Legal status ==

FDU-PB-22 is a [[Drugs controlled by the German Betäubungsmittelgesetz|controlled substance in Germany]] and is banned in Japan and Sweden.<ref>{{cite web | url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/maj/cannabinoider-foreslas-bli-klassificerade-som-halsofarlig-vara/ | title=Cannabinoider föreslås bli klassificerade som hälsofarlig vara | publisher=Folkhälsomyndigheten | date=28 May 2014 | accessdate=23 July 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-PB-22]]
* [[AM-2201]]
* [[QUCHIC|BB-22]]
* [[FUB-JWH-018]]
* [[AB-FUBINACA]]
* [[ADB-FUBINACA]]
* [[AMB-FUBINACA]]
* [[FUB-144]]
* [[FUB-APINACA]]
* [[FUB-NNE1]]
* [[FUB-PB-22]]
* [[MDMB-FUBICA]]
* [[MDMB-FUBINACA]]
* [[PB-22]]
{{Div col end}}

==References==
{{Reflist}}

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Fluoroarenes]]
[[Category:Naphthoylindoles]]
[[Category:Indolecarboxylates]]


{{cannabinoid-stub}}